







Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 6, 2018, Fred Oeschger resigned as a member of the board of directors of GeneThera, Inc. (the “Company”). In his resignation letter, Mr. Oeschger stated that he did not feel that Company information was communicated as timely or as completely as necessary for him to fulfill his obligations as a board member. He also stated that he disagreed with the Company’s decision to make filings and other public communications without board approval. A copy of his resignation letter is attached hereto as Exhibit 99.1.

The Company disagrees with Mr. Oeschger’s statements that information was not communicated in a timely manner. Management was trying to complete the filings on an expedited basis to meet a deadline imposed by the U.S. Securities and Exchange Commission. The Company provided Mr. Oeschger and other board members with drafts of the SEC reports as soon as it could and at least two days prior to the filing deadline and sought Mr. Oeschger’s comments but did not receive any. Management also was available during this time to discuss any of the draft filings with Mr. Oeschger, but Mr. Oeschger did not make any inquiries about the draft reports. A majority of the board of directors informally approved the filing of the reports before the reports were filed and later the board of directors formally ratified the filing of the reports. Hence, board approval was obtained.

The Company has furnished Mr. Oeschger with a copy of this Current Report on Form 8-K on December 13, 2018, providing him with the opportunity to furnish the Company with a letter addressed to the Company stating whether he agrees with the statements made by the Company herein and if not, stating the respects in which he does not agree. The Company will file any letter received by it from Mr. Oeschger as an exhibit by an amendment to this Form 8-K within two business days after receipt.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description of Exhibit
<u>99.1</u>	<u>Letter of Resignation from Fred Oeschger</u>



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, FC Global Realty Incorporated has duly caused this current report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 13, 2018 GENETHERA, INC.

By: /s/ Antonio Milici  
Antonio Milici  
Chief Executive Officer